Ashwani Rajput1, Thèrése Bocklage2, Alissa Greenbaum3, Ji-Hyun Lee4, Scott A Ness5. 1. Division of Surgical Oncology, Department of Surgery, University of New Mexico, Albuquerque, NM; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM. Electronic address: arajput@salud.unm.edu. 2. University of New Mexico Comprehensive Cancer Center, Albuquerque, NM; Department of Pathology, University of New Mexico, Albuquerque, NM. 3. Division of Surgical Oncology, Department of Surgery, University of New Mexico, Albuquerque, NM. 4. University of New Mexico Comprehensive Cancer Center, Albuquerque, NM; Division of Epidemiology, Biostatistics, and Preventive Medicine, Department of Internal Medicine, University of New Mexico, Albuquerque, NM. 5. University of New Mexico Comprehensive Cancer Center, Albuquerque, NM; Division of Molecular Medicine, Department of Internal Medicine, University of New Mexico, Albuquerque, NM.
Abstract
BACKGROUND: Colorectal cancer is a leading cause of cancer-related mortality, has a very broad mutational spectrum, and there is no clinically available biomarker that can predict which patients with stage II or stage III colorectal cancer will develop metastatic disease. PATIENTS AND METHODS: We used a targeted next-generation sequencing approach to analyze the mutational spectra in stage II and III colon cancer patient samples. RESULTS: Amidst a broad range of acquired mutations and variants, we found evidence of tumor heterogeneity that distinguished the tumors in different groups. When heterogeneity was quantified using the Mutant-Allele Tumor Heterogeneity (MATH) score, there was a strong correlation between higher MATH score and risk of metastases. CONCLUSIONS: Measures of tumor heterogeneity might be useful biomarkers for identifying patients with colon cancer who are at risk of developing metastases. This might allow for more specific, tailored follow-up and adjuvant therapies after standard surgery.
BACKGROUND:Colorectal cancer is a leading cause of cancer-related mortality, has a very broad mutational spectrum, and there is no clinically available biomarker that can predict which patients with stage II or stage III colorectal cancer will develop metastatic disease. PATIENTS AND METHODS: We used a targeted next-generation sequencing approach to analyze the mutational spectra in stage II and III colon cancerpatient samples. RESULTS: Amidst a broad range of acquired mutations and variants, we found evidence of tumor heterogeneity that distinguished the tumors in different groups. When heterogeneity was quantified using the Mutant-Allele Tumor Heterogeneity (MATH) score, there was a strong correlation between higher MATH score and risk of metastases. CONCLUSIONS: Measures of tumor heterogeneity might be useful biomarkers for identifying patients with colon cancer who are at risk of developing metastases. This might allow for more specific, tailored follow-up and adjuvant therapies after standard surgery.
Authors: Yu-Hsin Lin; Jan Friederichs; Michael A Black; Jörg Mages; Robert Rosenberg; Parry J Guilford; Vicky Phillips; Mark Thompson-Fawcett; Nikola Kasabov; Tumi Toro; Arend E Merrie; Andre van Rij; Han-Seung Yoon; John L McCall; Jörg Rüdiger Siewert; Bernhard Holzmann; Anthony E Reeve Journal: Clin Cancer Res Date: 2007-01-15 Impact factor: 12.531
Authors: Inès J Goossens-Beumer; Remco S Derr; Henk P J Buermans; Jelle J Goeman; Stefan Böhringer; Hans Morreau; Ulrich Nitsche; Klaus-Peter Janssen; Cornelis J H van de Velde; Peter J K Kuppen Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-10-14 Impact factor: 4.254
Authors: Cristian Tomasetti; Luigi Marchionni; Martin A Nowak; Giovanni Parmigiani; Bert Vogelstein Journal: Proc Natl Acad Sci U S A Date: 2014-12-22 Impact factor: 11.205
Authors: Nicholas McGranahan; Francesco Favero; Elza C de Bruin; Nicolai Juul Birkbak; Zoltan Szallasi; Charles Swanton Journal: Sci Transl Med Date: 2015-04-15 Impact factor: 17.956
Authors: Andrea Sottoriva; Haeyoun Kang; Zhicheng Ma; Trevor A Graham; Matthew P Salomon; Junsong Zhao; Paul Marjoram; Kimberly Siegmund; Michael F Press; Darryl Shibata; Christina Curtis Journal: Nat Genet Date: 2015-02-09 Impact factor: 38.330
Authors: Naser Davarzani; Lindsay C Hewitt; Matthew D Hale; Veerle Melotte; Matthew Nankivell; Gordon G A Hutchins; David Cunningham; William H Allum; Ruth E Langley; Shahab Jolani; Heike I Grabsch Journal: Dis Esophagus Date: 2020-08-03 Impact factor: 3.429
Authors: Alissa Greenbaum; David R Martin; Thèrése Bocklage; Ji-Hyun Lee; Scott A Ness; Ashwani Rajput Journal: Clin Colorectal Cancer Date: 2019-02-13 Impact factor: 4.481
Authors: Fabiana Bettoni; Cibele Masotti; Bruna R Corrêa; Elisa Donnard; Filipe F Dos Santos; Guilherme P São Julião; Bruna B Vailati; Angelita Habr-Gama; Pedro A F Galante; Rodrigo O Perez; Anamaria A Camargo Journal: Front Oncol Date: 2019-09-27 Impact factor: 6.244